RUKOBIA (fostemsavir tromethamine)
ANTIRETROVIRAL HIV - CD4 ATTACHMENT INHIBITORS · HIV INFECTION
VIIV HEALTHCARE
Drug class
Antiretroviral HIV - CD4 Attachment Inhibitors
Antiretroviral HIV CD4 attachment inhibitors constitute a specialized subclass of HIV entry inhibitors used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiretroviral HIV - CD4 Attachment Inhibitors
1 drugs in this class 1 manufacturers
Drugs in Antiretroviral HIV - CD4 Attachment Inhibitors
Filter & compare in the drug finder →
Opens the drug finder with Antiretroviral HIV - CD4 Attachment Inhibitors preselected. Add indication or manufacturer filters there.
Antiretroviral HIV CD4 attachment inhibitors constitute a specialized subclass of HIV entry inhibitors used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Represented primarily by fostemsavir, these agents selectively bind to the viral envelope glycoprotein gp120, preventing conformational changes necessary for the virus to attach to the host CD4 receptor and enter immune cells.
Their principal therapeutic role is as part of combination antiretroviral regimens for heavily treatment-experienced adults with multidrug-resistant HIV-1 who have failing current therapy due to resistance, intolerance, or safety considerations.
Because of their novel target, they demonstrate no cross-resistance to other major antiretroviral drug classes.
-
nih.gov
Antiretroviral HIV CD4 attachment inhibitors constitute a specialized subclass of HIV entry inhibitors used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection Represented primarily by fostemsavir, these agents selectively bind to the viral envelope glycoprotein gp120, preventing conformational changes necessary for the virus to attach to the host CD4 receptor and enter immune cells Their principal therapeutic role is as part of combination antiretroviral regimens for heavi...
-
nih.gov
Antiretroviral HIV CD4 attachment inhibitors constitute a specialized subclass of HIV entry inhibitors used in the treatment of human immunodeficiency virus type 1 (HIV-1) infection
-
nih.gov
Represented primarily by fostemsavir, these agents selectively bind to the viral envelope glycoprotein gp120, preventing conformational changes necessary for the virus to attach to the host CD4 receptor and enter immune cells
-
nih.gov
Their principal therapeutic role is as part of combination antiretroviral regimens for heavily treatment-experienced adults with multidrug-resistant HIV-1 who have failing current therapy due to resistance, intolerance, or safety considerations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.